XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Xilio Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$8.33−0.22 (-2.57%)
Close on Oct 19, 2026
- Market cap
- $161.64M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-95.9%
Net margin
-80.1%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +589.9% | – | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 97.9% | -132.5% | |
| Return on assets | – | – | -31.0% | |
| Current ratio | – | 0.93 | 2.58 | |
| Debt to equity | – | -0.09 | – | |
| Net debt to EBITDA | – | 0.25× | – | |
| Capex to revenue | – | – | 1.2% | |
| Diluted shares | – | 0M | 8M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Xilio Therapeutics generated $248.46M from operations and spent $4.01M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$248.46M
Used
$4.01M
Capital expenditure$4.01M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-80.1%
×Asset turnover0.39×
×Equity multiplier4.27×
=Return on equity, FY2025-132.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -80.1% | 0.39× | 4.27× | -132.5% |
| FY2024 | -918.0% | 0.10× | 2.43× | -214.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$35.04M
- Cash generatingOperating cash flow above zero-$4.99M
- Return on assets improvedROA up on the prior year-95.6% → -49.3%
- Earnings backed by cashOperating cash flow above net income-$4.99M vs -$35.04M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.21 → 2.58
- No dilutionShare count did not rise4M → 8M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.10 → 0.62